Thu, Apr 25, 2024
Glenmark Life Sciences Q4: Revenue from operations declined to Rs 536 crore for the period under review from Rs 621 crore a year ago
More >
Fri, Sep 29, 2023
Positive S&P on Glenmark Pharma. S&P changed the company's outlook from stable to positive. Outlook improved due to sale of 75% stake in Glenmark Life
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
